Fluorine in PDB 7mxg: PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800

Enzymatic activity of PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800

All present enzymatic activity of PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800:
2.1.1.320;

Protein crystallography data

The structure of PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800, PDB code: 7mxg was solved by M.Mctigue, Y.L.Deng, W.Liu, A.Brooun, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 109.39 / 2.40
Space group P 21 21 2
Cell size a, b, c (Å), α, β, γ (°) 98.407, 138.451, 178.452, 90, 90, 90
R / Rfree (%) 22.7 / 28.2

Other elements in 7mxg:

The structure of PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800 also contains other interesting chemical elements:

Chlorine (Cl) 2 atoms

Fluorine Binding Sites:

The binding sites of Fluorine atom in the PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800 (pdb code 7mxg). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total 2 binding sites of Fluorine where determined in the PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800, PDB code: 7mxg:
Jump to Fluorine binding site number: 1; 2;

Fluorine binding site 1 out of 2 in 7mxg

Go back to Fluorine Binding Sites List in 7mxg
Fluorine binding site 1 out of 2 in the PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800 within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F701

b:44.8
occ:1.00
F1 A:ZR4701 0.0 44.8 1.0
C14 A:ZR4701 1.4 44.8 1.0
C15 A:ZR4701 2.4 46.1 1.0
C13 A:ZR4701 2.4 43.0 1.0
H11 A:ZR4701 2.6 51.7 0.0
CL1 A:ZR4701 2.9 50.0 1.0
C16 A:ZR4701 3.6 43.8 1.0
CD1 A:LEU319 3.6 45.0 1.0
C12 A:ZR4701 3.6 41.9 1.0
CB A:PHE327 3.7 54.2 1.0
CG A:PHE327 4.0 55.2 1.0
CD1 A:TYR324 4.1 46.1 1.0
CD1 A:PHE327 4.1 56.0 1.0
C17 A:ZR4701 4.1 42.3 1.0
O A:HOH942 4.2 60.4 1.0
CE1 A:TYR324 4.4 46.3 1.0
H12 A:ZR4701 4.5 52.5 0.0
CA A:TYR324 4.6 48.4 1.0
O A:HOH889 4.7 48.3 1.0
H8 A:ZR4701 4.7 47.4 0.0
O A:THR323 4.7 48.4 1.0
OE2 A:GLU435 4.8 64.5 1.0
CD2 A:PHE327 4.8 56.2 1.0
C11 A:ZR4701 4.9 41.3 1.0
CG A:TYR324 4.9 46.1 1.0
O2 A:ZR4701 4.9 41.4 1.0
CE1 A:PHE327 5.0 56.6 1.0

Fluorine binding site 2 out of 2 in 7mxg

Go back to Fluorine Binding Sites List in 7mxg
Fluorine binding site 2 out of 2 in the PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 2 of PRMT5(M420T Mutant):MEP50 Complexed with Inhibitor Pf-06855800 within 5.0Å range:
probe atom residue distance (Å) B Occ
C:F701

b:44.4
occ:1.00
F1 C:ZR4701 0.0 44.4 1.0
C14 C:ZR4701 1.3 44.6 1.0
C15 C:ZR4701 2.3 46.7 1.0
C13 C:ZR4701 2.3 43.8 1.0
H11 C:ZR4701 2.6 52.6 0.0
CL1 C:ZR4701 2.9 50.6 1.0
CD1 C:LEU319 3.4 42.7 1.0
C16 C:ZR4701 3.6 45.5 1.0
C12 C:ZR4701 3.6 43.9 1.0
CB C:PHE327 3.6 56.3 1.0
CD2 C:PHE327 3.9 57.1 1.0
CG C:PHE327 3.9 56.6 1.0
C17 C:ZR4701 4.1 44.6 1.0
CD1 C:TYR324 4.1 42.4 1.0
O C:HOH1024 4.2 57.8 1.0
CE1 C:TYR324 4.4 41.8 1.0
H12 C:ZR4701 4.5 54.6 0.0
H8 C:ZR4701 4.6 47.9 0.0
CA C:TYR324 4.7 45.6 1.0
O C:HOH821 4.7 52.2 1.0
O C:THR323 4.8 45.8 1.0
CE2 C:PHE327 4.9 57.8 1.0
OE1 C:GLU435 4.9 67.2 1.0
C11 C:ZR4701 4.9 42.8 1.0
CG C:LEU319 4.9 42.0 1.0
CD1 C:PHE327 4.9 57.2 1.0
O2 C:ZR4701 4.9 42.7 1.0

Reference:

K.Jensen-Pergakes, J.Tatlock, K.A.Maegley, I.J.Mcalpine, M.A.Mctigue, T.Xie, C.P.Dillon, Y.Wang, S.Yamazaki, N.Spiegel, M.Shi, A.Nemeth, N.Miller, E.Hendrickson, H.Lam, J.Sherrill, C.Y.Chung, E.A.Mcmillan, S.K.Bryant, P.Palde, J.Braganza, A.Brooun, Y.L.Deng, V.Goshtasbi, S.E.Kephart, R.A.Kumpf, W.Liu, R.L.Patman, E.Rui, S.Scales, M.Tran-Dube, F.Wang, M.Wythes, T.A.Paul. Sam Competitive PRMT5 Inhibitor Pf-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated Nsclc with Decreased Liability of Drug Resistance. Mol.Cancer Ther. 2021.
ISSN: ESSN 1538-8514
PubMed: 34737197
DOI: 10.1158/1535-7163.MCT-21-0620
Page generated: Thu Nov 25 09:13:29 2021

Last articles

Zn in 8WB0
Zn in 8WAX
Zn in 8WAU
Zn in 8WAZ
Zn in 8WAY
Zn in 8WAV
Zn in 8WAW
Zn in 8WAT
Zn in 8W7M
Zn in 8WD3
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy